For sale India Tarceva Purchase India Tarceva 15101509702

Trade name: Tarceva in India Contact number: Common name: Erlotinib hydrochloride tablets Price: yuan
English trade name: r
English common name:
[Ingredients] Each tablet contains Erlotinib (exists in the form of erlotinib hydrochloride)
[Properties] Round, biconvex, white coated tablets,
[Product specifications] *3 tablets/bottle
[ Contraindications】It is prohibited for those who are allergic to this product and its ingredients.
[Indications] Erlotinib can be used as a third-line treatment for locally advanced or metastatic non-small cell lung cancer that has failed two or more chemotherapy regimens. R mutation needs to be detected in the first-line treatment of advanced non-small cell lung cancer, and it can be used if there is a mutation. Erlotinib combined with gemcitabine in the treatment of progressive pancreatic cancer
[Notes] This product must be used under the guidance of doctors with experience in the use of such drugs, and only in the National Oncology Drug Clinical Trial Base or tertiary A hospitals. use.
[Usage and Dosage] This product must be used under the guidance of doctors with experience in the use of such drugs, and can only be used in the national tumor drug clinical trial base or tertiary A hospitals. The recommended dose of erlotinib monotherapy for non-small cell lung cancer is /day, taken at least one hour before or one hour after eating. Continue treatment until disease progression or intolerable toxicity occurs. There is no evidence that patients benefit from continuing treatment after progression.
Tarceva instruction manual, Tarceva usage, Tarceva efficacy, Tarceva in India, Tarceva price in India, how to sell Tarceva in India, how much Tarceva is in India, where to buy Tarceva in India For sale, Tarceva purchasing agent price in India, wholesale Tarceva in India, Tarceva efficacy in India, price of Erlotinib Hydrochloride Tablets in India, instructions for Erlotinib Hydrochloride Tablets.
[Adverse Reactions] The most common adverse reactions are rash and diarrhea. The incidence rates of 3/degree rash and diarrhea are respectively. The median appearance time of rash is days and the median appearance time of diarrhea is days. The most common adverse reactions were rash and diarrhea. The incidences of grade 3/grade rash and diarrhea were 10 days and 10 days, respectively. The median onset time of rash was 3 days and the median onset time of diarrhea was 3 days. The most common adverse reactions include: rash, diarrhea, decreased appetite, fatigue, dyspnea, cough, nausea, infection, vomiting, stomatitis, itching, dry skin, conjunctivitis, keratoconjunctivitis, and abdominal pain. Pulmonary Toxicity There are rare reports of severe interstitial lung disease (), and even death, in patients treated with r or other solid tumors. In randomized controlled studies, the incidence was , and this incidence was the same in the r treatment group and the placebo group. Reported include: pneumonia, interstitial pneumonia, interstitial lung disease, bronchiolitis obliterans, pulmonary fibrosis, acute respiratory stress syndrome, and pulmonary effusion. Symptoms occurred from the day after treatment to more than one month, with a median onset time of days. Most patients often have confounding factors, such as previous chemotherapy/radiation therapy, existing parenchymal lung disease, lung metastasis or lung infection. When there are new and unexplained pulmonary symptoms, such as dyspnea, cough, fever, etc., examination and evaluation are required. Once diagnosed, use of r should be stopped and appropriate treatment should be taken. Hepatotoxic r treatment can cause asymptomatic increases in liver transaminase. Therefore, liver function should be reviewed regularly during treatment, including: transaminase, bilirubin, alkaline phosphatase, etc. If liver function damage is severe, the dose should be reduced or the drug should be discontinued. Liver damage is often temporary or accompanied by liver metastasis. Gastrointestinal bleeding is rarely reported and often occurs in patients taking warfarin at the same time. Therefore, patients taking warfarin or other anticoagulants at the same time should monitor their prothrombin time. Elderly patients: Safety and pharmacokinetics do not differ significantly between young and elderly patients; therefore, no dose adjustment is recommended when used in elderly patients.
[Details] Tarceva is a multi-target molecular targeted drug for the treatment of non-small cell lung cancer. It can significantly improve the quality of life of patients and prolong life. With the deepening of clinical research, Tarceva is clinically more effective for Tarceva recommendations are getting stronger day by day. Tarceva's mode of action is different from that of chemotherapy. It is a targeted therapy drug that can specifically target tumor cells and inhibit the formation and growth of tumors. It is a small molecule compound that can inhibit the signaling pathway of human epidermal growth factor receptor (R). It is a key component of the epidermal growth factor (also known as) signaling pathway and plays a role in the formation and growth of various tumor cells. All played an important role.
[Storage/Validity Period] It should be kept below 3 years. Valid for 3 months.